Sarepta Short Interest Hits 22.4% as Profitability Gains Support
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
sarepta-therapeuticsshort-squeeze
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Sarepta Therapeutics Inc. (SRPT) holds a short interest position exceeding 22.4% of its float, ranking it among the most heavily shorted small-cap healthcare stocks, according to data reported by finance.yahoo.com on June 6, 2026. This elevated short positioning builds against a backdrop of improving operational metrics, notably a reported 68% gross margin in its latest quarter. The stock trades near $138.00, a level that has seen significant volatility over the previous twelve months.
Short interest in speculative biotech firms often spikes ahead of binary regulatory or clinical events. The last comparable short buildup for Sarepta preceded the FDA's 2023 accelerated approval for Elevidys in Duchenne muscular dystrophy, where short interest peaked near 28% before the stock gained over 50% in the subsequent month. The current macro backdrop features elevated benchmark interest rates, which pressure high-multiple, pre-profitability growth stocks and embolden short sellers targeting cash-burn stories.
What changed to trigger this specific scrutiny now is the convergence of improved profitability metrics with an approaching catalyst window. The company’s recent quarterly report showed a significant expansion in gross margin, driven by its commercial gene therapy portfolio. This financial improvement collides with an upcoming regulatory decision for Elevidys' label expansion to ambulatory patients, expected by the end of 2026. Short sellers appear to be betting that the improved margins are insufficient to offset risks associated with the high-cost therapy’s market adoption and potential label restrictions.
Key financial and market data present a mixed picture. The short interest of 22.4% equates to approximately 20 million shares sold short against a float of roughly 89 million. This compares to a sector median short interest for biotech companies of approximately 8%. Sarepta’s market capitalization stands near $12.8 billion. The company’s reported gross margin improved from 61% in the prior-year quarter to 68% in the most recent quarter, a 700 basis point expansion.
Revenue for the latest quarter was $365 million, a 27% year-over-year increase. This growth significantly outpaces the iShares Biotechnology ETF (IBB), which is down 2% year-to-date. The company ended the quarter with $1.4 billion in cash and equivalents. The stock's 52-week range is $78.50 to $165.00, indicating high volatility. The current price of $138.00 sits 16% below its yearly high.
| Metric | Q1 2025 | Q1 2026 | Change |
|---|---|---|---|
| Gross Margin | 61% | 68% | +7 pp |
| Quarterly Revenue | $287M | $365M | +27% |
The high short interest creates potential for a sharp squeeze, which would benefit other heavily shorted biotech names with improving fundamentals, such as Arrowhead Pharmaceuticals (ARWR) and Beam Therapeutics (BEAM), by reducing sector-wide risk aversion. Conversely, a significant drop in SRPT on negative news would likely pressure the entire gene therapy sub-sector, including companies like CRISPR Therapeutics (CRSP) and Solid Biosciences (SLDB), due to amplified concerns over reimbursement and scalability.
A key risk to the short thesis is Sarepta’s dominant market position in DMD. A successful label expansion could trigger covering of a material portion of the short position, catalyzing a rapid upward move. Institutional positioning data shows hedge funds are net short, while many long-only healthcare funds maintain core positions, expecting regulatory clarity. Flow analysis indicates options volume is elevated, with a notable skew toward out-of-the-money call purchases, suggesting some traders are positioning for a potential upward catalyst.
The primary near-term catalyst is the FDA’s decision on the expanded label for Elevidys, with a Prescription Drug User Fee Act (PDUFA) date expected in late 2026. Investors will also scrutinize the company’s next earnings report, scheduled for early August 2026, for updates on gross margin trajectory and cash burn. The advisory committee meeting date for the label expansion, once announced, will be a critical volatility event.
Key technical levels to monitor include support near $125.00, which aligns with the 100-day moving average, and resistance around $155.00, near the March 2026 high. A sustained break above $155.00 on high volume could force short covering. Should the stock break below $125.00, it may test the stronger support zone between $110.00 and $115.00. Movement will be contingent on incremental data regarding therapy demand and payer negotiations.
High short interest indicates a large cohort of investors are betting the stock price will fall. For Sarepta, this reflects skepticism about its commercial execution, the high price of its therapies, and regulatory risks. It also creates a volatile setup where positive news can force short sellers to buy back shares to cover their positions, accelerating upward price moves in a short squeeze. This dynamic makes the stock more sensitive to catalyst events than peers with lower short interest.
During the 2021 meme stock frenzy, names like GameStop saw short interest exceed 100% of the float due to complex derivatives and failures to deliver. Sarepta's 22.4% is high for its sector but is a conventional, reportable level. The key difference is the underlying catalyst: meme stocks were driven by retail sentiment and social media, while Sarepta's short thesis is fundamentally anchored in biotech-specific risks like clinical outcomes and payer coverage, making its price action more tied to concrete news flow.
Historically, shorting biotech is high-risk due to binary outcomes. A 2022 study by a major investment bank showed that shorting stocks ahead of FDA decisions resulted in an average loss of 3% over the following month, as positive surprises are more common than expected. However, short sellers targeting companies with weak balance sheets and fading commercial prospects, as seen with the failures of several CAR-T and gene therapy firms in 2024, have recorded significant wins, demonstrating the strategy's dependence on precise fundamental analysis.
Sarepta's elevated short interest sets the stage for extreme volatility, with price direction hinging on imminent regulatory and commercial execution data.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.